Separation of the 100-kDa membrane protein mediating ADP-induced platelet shape change and activation from glycoprotein IIIa.
The following lines of evidence suggest that MP100, a putative ADP receptor, and GPIIIa are distinct proteins. [3H]FSBA incorporated equally into normal and thrombasthenic platelets (less than 5% GPIIIa), quantitatively as well as qualitatively. The dose-dependent inhibition of ADP-induced platelet shape change by FSBA is identical for normal and thrombasthenic platelets. Polyclonal rabbit antibodies precipitate MP100 and GPIIIa, but monoclonal antibodies directed against GPIIb/GPIIIa complex GPIIIa and P1A1 fail to precipitate the ADP receptor protein. A monoclonal antibody which inhibits ADP-induced platelet aggregation and fibrinogen binding fails to inhibit ADP-induced shape change. Thus, both functional and immunochemical evidence clearly indicates the distinct character of the ADP and fibrinogen receptors. We hypothesize that conformational changes in an ADP receptor on binding ADP or proteolytic changes as with chymotrypsin digestion may be responsible for exposure of the normally latent fibrinogen receptor (GPIIb/GPIIIa complex).
D000241:Adenosine / Q000031:analogs & derivatives; D000244:Adenosine Diphosphate / Q000494:pharmacology; D000911:Antibodies, Monoclonal; D001792:Blood Platelets / Q000032:analysis* / Q000166:cytology / Q000187:drug effects; D006801:Humans; D007120:Immunochemistry; D008970:Molecular Weight; D010980:Platelet Membrane Glycoproteins / Q000276:immunology / Q000302:isolation & purification* / Q000502:physiology; D011983:Receptors, Purinergic / Q000276:immunology / Q000302:isolation & purification*; D013915:Thrombasthenia / Q000097:blood
D000911:Antibodies, Monoclonal; D010980:Platelet Membrane Glycoproteins; D011983:Receptors, Purinergic; D000244:Adenosine Diphosphate; C010959:5'-(4-fluorosulfonylbenzoyl)adenosine; D000241:Adenosine